Jan 7, 2021 | Press Releases
Key Developments and Future Initiatives Position INVOcell® Within the Severely Underserved Fertility MarketSARASOTA, Fla., Jan. 7, 2021 – INVO Bioscience, Inc. (NASDAQ: INVO) (“Company”) (‘INVO”), a medical device company...
Nov 25, 2020 | Press Releases
– Malaysia represents a significant addressable market opportunity with approximately 10% of the population suffering from infertility.- idsMED is one of the largest and most well-respected medical solutions providers in the region.- Product registration is...
Nov 18, 2020 | Press Releases
SARASOTA, Fla., Nov. 18, 2020 – INVO Bioscience, Inc. (Nasdaq: INVO) developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, today announced the formation of its Scientific Advisory Board (SAB) with the appointment of...
Nov 16, 2020 | Press Releases
Company to Provide Investor Update on November 19 at 4:30pm ET (Details Below)SARASOTA, Fla., Nov. 16, 2020 — INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and...
Sep 30, 2020 | Press Releases
Joint Venture Targets the Large and Growing Mexico Market for Infertility ServicesSARASOTA, Fla., Sept. 30, 2020 – INVO Bioscience, Inc. (OTCQB: INVO) developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, announced today...
